Cryopreserved mouse hepatocytes retain regenerative capacity in vivo

被引:49
作者
Jamal, HZ
Weglarz, TC
Sandgren, EP
机构
[1] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA
[2] Univ Wisconsin, Sch Med, Div Gastroenterol, Madison, WI 53706 USA
关键词
D O I
10.1016/S0016-5085(00)70221-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Substitution of hepatocyte transplantation for whole liver transplants in selected individuals with liver disease could significantly expand the number of patients to benefit from use of scarce donor livers. However, successful hepatocyte transplantation may require that donor cells retain normal functional and proliferative capabilities and that they be readily available. Banking of cryopreserved hepatocytes would fulfill the latter requirement. Cryopreservation protocols have been developed that minimize hepatocyte injury and allow preservation of metabolic activity. The aim of this study was to assess cryopreserved hepatocyte proliferative capacity in vivo after thawing. Methods: Fresh and frozen/thawed mouse hepatocytes were transferred separately into the livers of recipient mice with transgene-induced liver disease, an environment that is permissive for clonal expansion of donor cell populations. Fresh and cryopreserved donor cells were compared for their ability to proliferate and replace damaged parenchyma. Results: Although cryopreservation decreased hepatocyte viability, individual viable frozen/thawed hepatocytes demonstrated clonal replicative potential identical to that: of fresh hepatocytes. Even after storage for 32 months in liquid nitrogen, transplanted hepatocytes constituting 0.1% of total adult hepatocyte number could repopulate a mean of 32% of recipient liver parenchyma. Conclusions: These findings suggest that cryopreserved hepatocytes represent an appropriate source of cells for therapeutic hepatocyte transplantation.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 15 条
[1]  
CHESNE C, 1993, HEPATOLOGY, V18, P406, DOI 10.1016/0270-9139(93)90026-J
[2]   Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation [J].
Fox, IJ ;
Chowdhury, JR ;
Kaufman, SS ;
Goertzen, TC ;
Chowdhury, NR ;
Warkentin, PI ;
Dorko, K ;
Sauter, BV ;
Strom, SC .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1422-1426
[3]   T-ANTIGEN EXPRESSION AND TUMORIGENESIS IN TRANSGENIC MICE CONTAINING A MOUSE MAJOR URINARY PROTEIN/SV40 T-ANTIGEN HYBRID GENE [J].
HELD, WA ;
MULLINS, JJ ;
KUHN, NJ ;
GALLAGHER, JF ;
GU, GGD ;
GROSS, KW .
EMBO JOURNAL, 1989, 8 (01) :183-191
[4]  
HOECKEL JL, 1990, CELL, V62, P447
[5]  
KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913
[6]   Hepatocyte transplantation [J].
Lake, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1463-1465
[7]   DEVELOPMENT OF AN OPTIMAL METHOD FOR THE CRYOPRESERVATION OF HEPATOCYTES AND THEIR SUBSEQUENT MONOLAYER-CULTURE [J].
LAWRENCE, JN ;
BENFORD, DJ .
TOXICOLOGY IN VITRO, 1991, 5 (01) :39-&
[8]   OPTIMIZATION OF CRYOPRESERVATION PROCEDURES FOR RAT AND HUMAN HEPATOCYTES [J].
LORETZ, LJ ;
LI, AP ;
FLYE, MW ;
WILSON, AGE .
XENOBIOTICA, 1989, 19 (05) :489-498
[9]  
NOVICKI DL, 1982, IN VITRO CELL DEV B, V18, P393
[10]   Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I [J].
Overturf, K ;
AlDhalimy, M ;
Tanguay, R ;
Brantly, M ;
Ou, CN ;
Finegold, M ;
Grompe, M .
NATURE GENETICS, 1996, 12 (03) :266-273